glp-1 news past 3 days Alarming rise in weight loss drug overdoses Two Years After Stopping GLP-1s,

The FLOW trial, published in 2024, was the first dedicated renal outcomes trial for a GLP-1 medication

But its influence doesn't stop at the gut wall

The path forward requires a commitment to innovation, a focus on equitable access, and a collaborative spirit to navigate the challenges and unlock the full potential of GLP-1 receptor agonists

Albiglutide: first global approval

Bariatric surgery not only facilitates weight loss, but often leads to improvements in obesity-related comorbidities such as type 2 diabetes, hypertension, and sleep apnea

Introducing GLP-3 RT GLP-3 represents a newer area of research in the GLP family